杜普伊特倫攣縮症市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型（診斷、治療）、按疾病類型、按最終用途、按地區和競爭細分，2020-2030 年

2024 年全球杜普伊特倫攣縮症市場價值為 46 億美元，預計在預測期內將穩定成長，到 2030 年年複合成長率(CAGR) 為 4.25%。

杜普伊特倫攣縮症，也稱為杜普伊特倫攣縮，是一種影響手掌和手指皮膚下結締組織的進行性疾病。該病以 19 世紀首次描述該疾病的法國外科醫生 Baron Guillaume Dupuytren 的名字命名，主要導致手指向內彎曲至手掌，導致功能受限。

儘管仍在進行研究，但確切病因仍不清楚，但遺傳易感性被廣泛認為是一個主要的促成因素。有家族病史的人患病風險明顯較高。此外，北歐和斯堪的納維亞血統的人群的盛行率明顯較高。其他公認的風險因素包括年齡成長、男性（男性患此病的可能性幾乎是女性的六倍）、吸煙和飲酒。

此疾病的特徵是皮膚下形成增厚的纖維組織，稱為掌筋膜。隨著時間的推移，這種組織收縮，將手指向內拉。最初的症狀可能包括手掌出現小腫塊或結節，這些腫塊或結節可能會融合成導致手指攣縮的繩狀結構。這種疾病最常影響無名指和小指，但也可能影響其他手指。這些攣縮會嚴重損害手部功能，使抓握物體或握手等日常任務變得困難。

關鍵市場促進因素

杜普伊特倫攣縮盛行率上升

主要市場挑戰

認知有限，診斷延遲

主要市場趨勢

轉向以病人為中心的護理

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：杜普伊特倫攣縮症市場展望

• 市場規模和預測
  • 按價值
  • 市場佔有率和預測
  • 按類型（診斷（身體檢查、X 光）、治療（手術、放射療法、針刺腱膜切開術、類固醇注射、酵素注射、職業療法、其他））
  • 依疾病類型（I 型、II 型、III 型）
  • 依最終用途（醫院、診所、學術和研究機構、其他）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美杜普伊特倫攣縮症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲杜普伊特倫攣縮症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區杜普伊特倫攣縮症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美杜普伊特倫攣縮症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲杜普伊特倫攣縮症市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

第 16 章：策略建議

第17章調查會社について,免責事項

Global Dupuytren's disease market was valued at USD 4.60 billion in 2024 and is projected to experience steady growth over the forecast period, with a compound annual growth rate (CAGR) of 4.25% through 2030.

Dupuytren's disease, also known as Dupuytren's contracture, is a progressive condition that affects the connective tissue beneath the skin of the palm and fingers. Named after the French surgeon Baron Guillaume Dupuytren, who first described the disease in the 19th century, it primarily causes fingers to bend inward toward the palm, resulting in functional limitations.

While the exact etiology remains unclear despite ongoing research, genetic predisposition is widely acknowledged as a major contributing factor. Individuals with a family history of the condition are at significantly higher risk. Additionally, the prevalence is notably higher among people of Northern European and Scandinavian descent. Other recognized risk factors include advancing age, male gender (with men being nearly six times more likely to develop the condition), smoking, and alcohol consumption.

The disease is characterized by the formation of thickened fibrous tissue-referred to as palmar fascia-beneath the skin. Over time, this tissue contracts, pulling the fingers inward. Initial symptoms may include small lumps or nodules in the palm, which can merge into cord-like structures that lead to finger contractures. The condition most commonly affects the ring and little fingers but may involve other digits as well. These contractures can significantly impair hand function, making routine tasks such as gripping objects or shaking hands challenging.

Key Market Drivers

Rising Prevalence of Dupuytren's Contracture

A significant factor fueling the market's growth is the increasing global prevalence of Dupuytren's contracture. The condition affects approximately 4% of the global population, with disproportionately higher incidence rates in Northern European populations. The male-to-female ratio stands at 5.9:1, indicating a marked gender disparity.

As the number of diagnosed cases continues to rise, so does the demand for diagnostic solutions, therapeutic options, and patient care services. Incidence increases with age, with a majority of cases occurring in individuals over the age of 50. The condition affects both hands in nearly 45% of patients, with unilateral cases more commonly involving the right hand.

As global life expectancy increases-particularly in developed markets such as North America and Europe-a growing segment of the population becomes susceptible to the disease, thereby expanding the potential patient pool. This demographic trend is expected to sustain demand for accessible and effective treatment options.

Dupuytren's contracture is significantly more prevalent among individuals of Northern European descent, with prevalence rates ranging from 4% to 39% in certain populations. Genetic predisposition further elevates the risk, particularly for individuals with a family history of the disease. As awareness of hereditary risk factors improves, early diagnosis and proactive treatment-seeking behaviors are expected to grow, contributing to market expansion.

Historically, underdiagnosis and low awareness among patients and healthcare providers have hindered treatment efforts. However, recent advancements in education, awareness campaigns, and diagnostic technologies have led to increased recognition and more timely diagnoses.

Key Market Challenges

Limited Awareness and Delayed Diagnosis

Despite the increasing prevalence of Dupuytren's disease, limited public and clinical awareness continues to pose a challenge. Early symptoms are often mistaken for normal signs of aging or benign discomfort, leading to delayed diagnosis and missed opportunities for early intervention.

Healthcare providers play a pivotal role in improving early detection, but the relative rarity of the condition and the absence of standardized diagnostic criteria can hinder accurate recognition. Addressing this challenge requires targeted educational initiatives aimed at both medical professionals and the public to raise awareness of risk factors, symptoms, and treatment options.

Key Market Trends

Shift Toward Patient-Centric Care

The healthcare sector is undergoing a notable transformation toward patient-centric models of care, where patients play an active role in managing their treatment pathways. This shift is particularly pertinent to conditions like Dupuytren's disease, where treatment outcomes directly influence quality of life.

As patients become more informed and engaged, there is a growing demand for treatment options that align with individual lifestyles, preferences, and goals. This evolving expectation is encouraging the development of a broader spectrum of therapeutic interventions, emphasizing personalization and improved patient experience.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC.

Report Scope:

In this report, the Global Dupuytren's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dupuytren's Disease Market, By Type:

• Diagnosis {Physical Examination, X-ray}
• Treatment {Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others}

Dupuytren's Disease Market, By Disease Type:

• Type I
• Type II
• Type III

Dupuytren's Disease Market, By End-use:

• Hospitals
• Clinics
• Academic & Research Institute
• Others

Dupuytren's Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren's Disease Market.

Available Customizations:

Global Dupuytren's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Dupuytren's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. Market Share & Forecast
  • 5.1.3. By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))
  • 5.1.4. By Disease Type (Type I, Type II, Type III)
  • 5.1.5. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)
  • 5.1.6. By Company (2024)
  • 5.1.7. By Region
• 5.2. Market Map

6. North America Dupuytren's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dupuytren's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Mexico Dupuytren's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Canada Dupuytren's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End-Use

7. Europe Dupuytren's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dupuytren's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End-Use
  • 7.3.2. Germany Dupuytren's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Dupuytren's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Dupuytren's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Dupuytren's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End-Use

8. Asia-Pacific Dupuytren's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Dupuytren's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Dupuytren's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End-Use
  • 8.3.3. South Korea Dupuytren's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End-Use
  • 8.3.4. Japan Dupuytren's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Dupuytren's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End-Use

9. South America Dupuytren's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dupuytren's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End-Use
  • 9.3.2. Argentina Dupuytren's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End-Use
  • 9.3.3. Colombia Dupuytren's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End-Use

10. Middle East and Africa Dupuytren's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dupuytren's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Saudi Arabia Dupuytren's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End-Use
  • 10.3.3. UAE Dupuytren's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Nantong Jinghua Pharmaceutical Co., Ltd
• 15.5. Actiza Pharmaceutical Private Limited
• 15.6. Endo International plc
• 15.7. Spear Pharmaceuticals
• 15.8. Hikma Pharmaceuticals PLC
• 15.9. Bristol-Myers Squibb
• 15.10. Glaxosmithkline PLC

16. Strategic Recommendations

17. About Us & Disclaimer